Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Construction of an unmarked recombinant BCG expressing a pertussis antigen by auxotrophic complementation: Protection against Bordetella pertussis challenge in neonates

Texto completo
Autor(es):
Nascimento, Ivan P. [1] ; Dias, Waldely O. [1] ; Quintilio, Wagner [2] ; Hsu, Tsungda [3] ; Jacobs, Jr., William R. [4, 3] ; Leite, Luciana C. C. [1]
Número total de Autores: 6
Afiliação do(s) autor(es):
[1] Inst Butantan, Ctr Biotecnol, BR-05503900 Sao Paulo - Brazil
[2] Inst Butantan, Div Controle Qualidade, BR-05503900 Sao Paulo - Brazil
[3] Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 - USA
[4] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 - USA
Número total de Afiliações: 4
Tipo de documento: Artigo Científico
Fonte: Vaccine; v. 27, n. 52, p. 7346-7351, DEC 9 2009.
Citações Web of Science: 17
Resumo

Mycobacterium bovis BCG has long been investigated as a candidate for heterologous antigen presentation. We have previously described an rBCG-Pertussis that confers protection against challenge with Bordetella pertussis in neonate and adult mice. In order to obtain stable expression in vivo, we constructed an unmarked BCG lysine auxotrophic and a complementation vector containing the lysine and the genetically detoxified S1 pertussis toxin genes, both under control of the same promoter. Complemented BCG-Delta lysine growth and expression of the pertussis antigen were stable, without the use of an antibiotic marker. Our results show that the complemented rBCG-Delta lysA-S1PT-lysA(+)(kan(-)), which is now suitable to be evaluated in clinical trials, maintains similar characteristics of the original rBCG-pNL71S1PT strain, such as the antigen expression level, cellular immune response and protection against the same model challenge in neonatal-immunized mice. (C) 2009 Elsevier Ltd. All rights reserved. (AU)

Processo FAPESP: 96/11539-0 - Desenvolvimento de uma vacina de BCG recombinante - DPT
Beneficiário:Luciana Cezar de Cerqueira Leite
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 02/01748-4 - Influência das propriedades adjuvantes de toxinas bacterianas expressas em BCG recombinante na resposta induzida contra micobactérias
Beneficiário:Ivan Pereira Nascimento
Linha de fomento: Bolsas no Brasil - Pós-Doutorado